Compare CBUS & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBUS | IOBT |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 26.6M |
| IPO Year | 2017 | 2021 |
| Metric | CBUS | IOBT |
|---|---|---|
| Price | $3.35 | $0.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $20.00 | $2.25 |
| AVG Volume (30 Days) | 539.1K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.27 | 26.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,262,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $99.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 134.56 | N/A |
| 52 Week Low | $1.09 | $0.21 |
| 52 Week High | $3.80 | $2.79 |
| Indicator | CBUS | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 43.30 |
| Support Level | $1.34 | $0.32 |
| Resistance Level | N/A | $0.40 |
| Average True Range (ATR) | 0.37 | 0.03 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 76.69 | 33.75 |
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.